Novo Nordisk announced that its Ozempic® (semaglutide injection) is now publicly reimbursed in the province of Ontario. A once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated alongside diet and exercise to improve glycemic control in adults with type 2 diabetes when metformin is inappropriate. The drug can be used with metformin, sulfonylurea and basal insulin with metformin.
The product was approved in January 2018 after it was extensively studied in the SUSTAIN clinical trial program, which involved more than 8,000 adults with type 2 diabetes. In the SUSTAIN program, Ozempic® was studied in combination with oral-antidiabetic agents and basal insulin.
Public Access & Reimbursement Important
Dr. Dona Goldenberg reports on the critical importance of public access for type 2 diabetes treatment options. She notes that “When left uncontrolled, diabetes can cause serious health problems that can negatively impact a person’s quality of life. Being able to prescribe Ozempic® which patients only need to take once a week, is an important step to helping to control the condition and reduce those risks.”